Advertisement
Advertisement
U.S. markets close in 1 hour 57 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Salarius Pharmaceuticals, Inc. (SLRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.7356-0.1044 (-5.67%)
As of 01:49PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.8400
Open1.8900
Bid1.7100 x 900
Ask1.7400 x 1100
Day's Range1.7100 - 1.8490
52 Week Range1.7000 - 16.7500
Volume13,164
Avg. Volume43,241
Market Cap3.954M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.3770
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SLRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Salarius Pharmaceuticals, Inc.
    Daily – Vickers Top Insider Picks for 12/02/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

    60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer

  • GlobeNewswire

    Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

    HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and nine months ended September 30, 2022 and provided a business update. Highlights of the third quarter of 2022 and recent weeks include: Financial Highlights Cash and cash equivalents were $16.8

  • GlobeNewswire

    Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

    HOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that two abstracts related to the company’s compounds have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022 in New Orleans and virtua

Advertisement
Advertisement